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a  b  s  t  r  a  c  t
Aim: Head and neck squamous cell carcinoma (HNSCC) are one of the worst prognosis can-
cers  with high mortality of patients. The treatment strategy is primarily based on surgery
and  radiotherapy but chemotherapy is also used. Every year the knowledge concerning
HNSCC biology is updated with new elements such as the recent discovered molecules –
long non-coding RNAs. Long non-coding RNAs are involved in regulatory processes in the
cells. It has been revealed that the expression levels of lncRNAs are disturbed in tumor cells
what  results in the acquisition of their specific phenotype. lncRNAs influence cell growth,
cell  cycle, cell phenotype, migration and invasion ability as well as apoptosis. Development
of  the lncRNA panel characteristic for HNSCC and validation of specific lncRNA functions





the  context of lncRNA exp
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.  Head  and  neck  cancers
ancers of the head and neck area are prevalent in patients
ver 50 years old but they are becoming more  common in
oung adults. Main features of head and neck squamous
ell carcinoma (HNSCC) is poor—five-year survival (approxi-
ately 50%), depending mostly on the anatomical localization
f the tumor. Oral cavity, oropharynx, hypopharynx, larynx
nd nasopharynx are the localization sites of squamous cell
arcinoma.1 The development of HNSCC is a multistep pro-
ess of changes of normal mucosa and is often preceded by
remalignant lesions such as leukoplakia.2,3 HNSCC is mainly
aused by exogenous factors such as cigarette smoking, alco-
ol consumption, unhealthy diet and HPV or EBV infections.4,5
PV positive tumors are molecularly and clinically distinct
rom HPV negative ones and HPV status is a significant prog-
ostic factor.1 Complete genetic characterization of HNSCC
as described in the Cancer Genome Atlas Project. Analy-
is of 279 patients confirmed the already known changes in
he genome and transcriptome and revealed the existence
f previously undescribed molecular characteristics. Genet-
cs and biology of HNSCC largely depend on the anatomical
ocation of the tumor and the effect of carcinogenic factors.
PV-positive tumors are characterized by mutations in the
IK3CA gene, TRAF3 gene loss and E2F1 gene amplification.
he second group, HPV-negative tumors, has mutations in
CND1, FADD, BIRC2, YAP1, CASP8 or HRAS and in other genes
nvolved in the regulating cell cycle, cell death and NF-kB path-
ay. It has been shown that a common feature of HPV-positive
nd HPV-negative cancers are changes in TP63, SOX2 and
IK3CA genes. Characteristic features of HNSCC associated
ith smoking are mutations in the TP53 gene, inactivation
f CDKN2A and changes in the genes associated with oxida-
ive stress. It was noted that oral cancers, which have better
esponses to treatment, possess mutations in genes such as
RAS, PIK3CA, CASP8, NOTCH1 or TP53. Other types of HNSCC
ave changes in the NSD1, WNT  and NFE2L2 pathway genes
especially cancers of the larynx). Regarding genetic back-
round, HNSCCs were divided into four types of cancers: (i)
asic (31% of cases), (ii) mesenchymal (27%), (iii) atypical (24%)
nd (vi) typical (18%).6
Biological knowledge of HNSCC continues to grow every
ear. Established by TCGA, molecular portrait of protein-
oding genes is a helpful tool to test selected biomarkers.
n previous report we  indicated that several genes showed
ignificant changes in expression in the HNSCC compared
o healthy tissues based on cancer pathway analyses. And
ome of them can be used as predictive or prognostic factors.7
part from protein-coding RNAs, more  and more  research
ocused on non-coding RNAs (ncRNAs). It was shown that
cRNAs—like miRNAs which can distinguish between can-
er and healthy tissue—are present and dysregulated in
atients’ serum and can be used as a new, promising class
f biomarkers.8–11 In the era of next generation sequencing,
he interest of ncRNAs is growing and new types of ncRNAs
re discovered and thoroughly analyzed. One of the recently
ndicated molecules involved in the pathogenesis of HNSCC
re long non-coding RNA (lncRNA).therapy 2 2 ( 2 0 1 7 ) 378–388 379
2.  Long  non-coding  RNA
Approximately 62% of human genome is transcribed, where
about 30% of the transcripts correspond to exonic and intronic
regions of protein-coding genes. The rest of them are mainly
lncRNA in intragenic regions or antisense strands.12 Long
non-coding RNAs (lncRNAs) are a class of functional RNA
molecules (consisting of at least 200 nucleotides) that are
not translated into proteins and many  of them are uniquely
expressed in a specific type of tissue or cancer type.13 It should
be noted that some of RNAs possess dual functions of cod-
ing and non-coding molecules.14 In the group of bifunctional
RNAs, the following types can be distinguished: (i) lncRNA
with small open reading frames (sORFs); (ii) coding and non-
coding mRNAs as well as coding and non-coding isoforms (iii)
by alternative splicing and (iv) with allele-specific features.14
Expression of lncRNAs is regulated in a specific way, more  than
mRNAs, depending on cell types. In most cases they are evo-
lutionarily conserved with regard to their function, secondary
structure and regions of homology despite minimal overall
sequence similarity.15–17
lncRNA biogenesis depends on lncRNA gene localization
and share some features of protein-coding RNAs. The pri-
mary  transcripts are proceeded by RNA polymerase II and
they often undergo special processing events that were not
observed in the case of mRNAs. The products of these pro-
cesses are lncRNAs as well as mRNAs, short non-coding
RNAs (pre-miRNAs, tRNA-like ncRNA) and different unstable
forms of RNA molecules.18 The intragenic lncRNAs (lin-
cRNAs) can be encoded either in the sense or antisense
orientation to host mRNAs and share hosts’ promoters and
enhancers.19 However, some promoters of genes coding
lncRNA and protein-coding RNAs are under distinct regula-
tory regime. Moreover, lncRNAs transcription is more  sensitive
to Dicer-miRNA-Myc circuit than protein-coding RNAs with
Myc  binding sites.18,20 The lncRNA mechanisms of action
depends on cellular localization. In the case of nuclear local-
ization, they are involved in chromatin, transcriptional and
RNA processing events; while in the case of cytoplasmic local-
ization they are involved in mRNA  stability or translation and
they have influence on signaling cascades. Generally lncR-
NAs function as modulators of gene expression in cells in
different ways: (i) signaling lncRNAs act as molecular sig-
nals due to specific biological events such as cellular stress
leading to transcription activation of specific genes; (ii) decoy-
ing lncRNAs behave as modulators of protein factors such as
transcription factors and chromatin modulators by binding to
them and inhibiting their function consequently suppress-
ing genes; (iii) guiding lncRNAs act as guides for specific
ribonucleoprotein complexes and promote chromatin mod-
ification of target and (iv) lncRNA scaffolds modification of
existing ribonucleoprotein complexes leads to transcriptional
activation or repression, Fig. 1.19–21 Another division of lncR-
NAs includes their regulative mechanism relating to location
of controlled genes (i) close to transcription site of lncRNA
(the same chromosome) named as cis-acting lncRNA (e.g.
lncRNA-p21) and (ii) distant genes named trans-acting lncRNA
(e.g. HOTAIR).19
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Fig. 1 – lncRNAs function as modulators of gene expression in cell. (A) Signaling-lncRNAs act as molecular signals due to
specific biological events, such as cellular stress and lead to transcription activation of specific genes. (B) Decoying-lncRNAs
behave as modulators of protein factors such as transcription factors as well as chromatin modulators by binding to them
and inhibit their function leading to genes suppression. (C) Guide-lncRNAs act as guide for specific ribonucleoproteins
complexes and promote chromatin modification of target genes. (D) lncRNA scaffolds modification of existing
tionribonucleoproteins complexes leads to transcriptional activa
It should be underlined that some lncRNAs encode miR-
NAs in their own primary or mature sequences. Moreover,
some lncRNAs, named competing endogenous RNAs (ceR-
NAs), can possess multiple binding sites of specific miRNAs.
ceRNAs protect target mRNA  against repression by miRNA,
e.g. H19 lncRNA acts as molecular sponge for the let-7
family.21–23
Like miRNAs, lncRNAs can be divided into two functional
classes—suppressor and oncogenic. However, some of them
can play dual functions depending on the type of cancer, for
example BANCR or H19 lncRNAs.24
The role of lncRNAs in cancer is deeply examined and it
is thought that they control important hallmarks of tumori-
genesis. Processes responsible for local tumor growth (in situ)
such as cell proliferation, regulation of cell death or angiogen-
esis are regulated by lncRNAs.20 The role of lncRNAs is not or repression.
only involved in local tumor growth but lncRNAs also have
influence on invasion and metastatic processes.14
Yan et al. presented comprehensive characterization of
lncRNA across 13 cancer types based on TCGA data. They
concluded that dysregulation of lncRNA is highly cancer-type
specific. More  than 60% is uniquely expressed across can-
cers and only a few are dysregulated in all of analyzed cancer
types.25 HOTAIR, MALAT1, H19, BANCR, CCAT1 & CCAT2, UCA1
and FOXCUT are described as lncRNAs associated with cancer
progression.24 It is suggested that the imbalance of coding and
non-coding transcripts of protein-coding genes may be asso-
ciated with the cancerogenesis.14 Among important events
leading to dysregulation of lncRNAs are changes in somatic
copy numbers of lncRNA genes, DNA methylation patterns
in the promoter regions of lncRNA genes as well as cancer-
associated SNPs (Single Nucleotide Polymorphisms).25–27
reports of practical oncology and radiotherapy 2 2 ( 2 0 1 7 ) 378–388 381
































arcinoma; LSCC, laryngeal squamous cell carcinoma, TSCC
It is postulated that lncRNAs are one of the important
lements maintaining anti-cancer drug and irradiation resis-
ance and could be used as biomarkers.28–30 Currently, many
tudies focus on the use of lncRNAs as predictors of survival
n human cancers. However, many  available studies are char-
cterized by inaccurate results and poor methodology, which
ndicates a strong need of further research.31
.  lncRNAs  in  head  and  neck  cancers
he global expression analysis of lncRNA presents profile
f dysregulated lncRNA in cancer tissue of HNSCC. Four
ioinformatic analysis of available data, three experimen-
al microarray studies and one experimental next-generation
equencing revealed similarities and differences among vari-
us studies.32–41
The inaccuracies may be caused by differences in examined
roups or samples (such as anatomical sites) reflecting genetic
iversity. As showed in Fig. 2, the expression pattern of lncR-
As is closely connected with specific localization of HNSCC.
owever, some lncRNAs with strong prognostic ability of over-
ll survival, disease-free survival or recurrence-free survival
re proposed and they are independent of gender, organ site,
umor stage or TP53 status.32,35,37,39 Some lncRNAs could also
e used as the virus infection indicators32 while others may
erve as metastasis and disease progression markers.34 The
nteractions between lncRNA and mRNA  are indicated and
onnected with the regulation of transcription, apoptosis, cell
rowth and proliferation, migration and movement, cell dif-
erentiation, inflammatory and immune response, as well as
etabolic and biosynthesis processes in the cell.32–41lncRNAs regulate many  hallmarks of cancer, such as
he malignant phenotype, by regulation of epithelial-to-
esenchymal transition process (EMT) and influence on
ancer invasion and metastasis.24 Unfortunately, knowledgegue squamous cell carcinoma.)
about lncRNAs involved in EMT process in HNSCC is still poor
and there is no experimental evidence for most of lncRNAs.
However, many  dysregulated lncRNAs in HNSCC probably reg-
ulate transcripts associated with EMT  or invasion/metastasis
processes, which we indicated in Table 1. The clear evi-
dence of EMT process regulation by MALAT1, lncRNA-ROR,
lnc-KTCTD6-3, lnc-LCE5A1, NKILA and HOTAIR was indicated
in HNSCC, and shown in Fig. 3.
It is well known that a tumor is not restricted to only one
type of cancer cell, but various types with different phen-
otypes. One of which is cancer initiating cells (CICs), with
unique genetic and behavior characteristics. Many  studies
characterize CIC populations in HNSCC and connect them
with chemo or radioresistance.42–46 It was indicated that
lncRNAs can regulate pluripotency and differentiation of
embryonic stem cells (ESCs) or induce pluripotent stem cells
(iPSCs). They are also important regulators of adult stem
cells.19,47 One of the well-known lncRNAs implicated with
pluripotency and tumorigenesis is SOX2OT. It was shown that
SOX2OT positively regulates SOX2 and OCT4 genes—well-
known markers of CICs. Moreover, expression of SOX2OT and
SOX2 is increased in suspension culture of breast cancer cells
compared to adherent ones.48 It should be noted that hypoxia-
related lncRNAs play important roles in tumorigenesis and
could have important roles in CICs biology.49 These results
support the statement that lncRNAs are implicated in CICs
populations in HNSCC. Unfortunately, no experimental evi-
dence directly connects specific lncRNA and CICs in HNSCC.
The most studied lncRNAs in HNSCC are: HOTAIR, UCA1,
LET, MEG3, MALAT1, H19 and NAG7. Their predicted targets, as
well as other lncRNA indicated in HNSCC, are listed in Table 1.
They are involved in many  important cellular processes such
as proliferation, migration and invasion, and apoptosis or phe-
notype regulation.
HOTAIR is a non-coding transcript of 2.2 kb that is tran-
scribed from the HOXC locus at chromosome 12 but acts in
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Fig. 3 – Role of lncRNA in epithelial-to-mesenchymal and mesenchymal-to-epithelial processes in HNSCC.
Epithelial-to-mesenchymal (EMT) and mesenchymal-to-epithelial (MET) processes are one of the hallmarks of cancer
progression. EMT  process leads to change the cell phenotype, loose its polarity, cellular and extracellular junctions causing
t rolcell more  motility. Probably some of lncRNAs have importan
transit at the HOXD locus at chromosome 2 thereby induces
the transcription silencing.50 The 5′-end of HOTAIR can bind
chromatin-modifying complexes, whereas the 3′-end is able
to bind histone demethylase I complex. Thanks to that,
HOTAIR regulates the methylation of histone H3K27 site or the
demethylation of H3K4me2 in genes related with the prolifer-
ation, apoptosis or metastasis of tumor cells.51 The expression
of HOTAIR was found to be increased in many  subtypes of
HNSCCs. Increased expression of HOTAIR was also associated
with metastasis in breast and colorectal cancer patients.52
In laryngeal squamous cell carcinoma (LSCC) HOTAIR was
found to be overexpressed compared to a noncancerous tissue.
It is suggested that HOTAIR promotes the malignant pro-
gression of LSCC. High expression of HOTAIR was correlated
with poor differentiation cancers, lymph node metastasis,
resistance to apoptosis and more  advanced clinical stages of
LSCC.50
In oral squamous cell carcinoma (OSCC) a higher expres-
sion of HOTAIR compared to metastatic and non-metastatic
tumors was observed. In addition, the level of HOTAIR corre-
lated with lymph node metastasis,53 tumor size, clinical stage
and histological differentiation.54 No differences were found
in gene expression between males and females. Similarly, the
age of patients did not have an impact on the level of expres-
sion of HOTAIR in OSCC.53
Wang et al. described the expression levels of HOTAIR and
miR-21 in exosomes isolated from blood of LSCC patients.
The expression of HOTAIR and miR-21 was increased and
correlated with clinical stages, T classification and lymph
node metastasis.52 In addition, combined over-expression of
miR-21 and HOTAIR can discriminate patients who are at the
risk of developing LSCC with 94.2% of sensitivity and 73.5% of
specificity.52 For nasopharyngeal carcinoma (NPC) patients,
HOTAIR is postulated as an independent prognostic marker
for patients’ progression and survival. However, it is alsoe in this process.
supposed to be more  useful in advanced cases of the disease.
Like in other HNSCC cancers, high expression of HOTAIR is
connected with larger tumor size and advanced clinical stage.
In vitro experiments indicated that HOTAIR is up-regulated in
invasive NPC cell lines compared to low-invasive ones and
knockdown of HOTAIR causes inhibition of cell proliferation,
migration and invasion55 and stimulation of cell apoptosis.56
It is postulated that HOTAIR may stimulate tumorigenesis
in NPC by pro-proliferation and pro-angiogenesis processes.
The angiogenic function is manifested through direct tran-
scription activation of VEGFA as well as by GRP78-mediated
up-regulation of VEGFA and Ang2 expression.56
HOTAIR was also examined in OSCC cell lines. The expres-
sion was highly increased in OSCC Tca8113, UM-1 and CAL-27
cell lines compared to normal oral epithelial cell line.54
Knockdown of HOTAIR in Tca8113 cells significantly reduced
proliferation ratio by arresting the cell cycle and inducing apo-
ptosis, which shows correlation of its expression with tumor
size. The expression HOTAIR is negatively correlated with E-
cadherin in patients’ samples and cell lines. HOTAIR regulates
E-cadherin through contribution of EZH2 and H3K27me3 bind-
ing with E-cadherin promoter. HOTAIR plays important role in
carcinogenesis and it is not surprising that OSCC patients with
over-expression of HOTAIR have poor OS and DFS.54 Addition-
ally, Kong et al. observed that depletion of HOTAIR induced
mitochondrial-related cell death and involved pathways such
as Bcl-2, BAX, Caspase-3, cleaved Caspase-3 and Cytochrome
c. Injection of HOTAIR siRNA into tumors in a mouse model
inhibited their growth.57 Regulation of HOTAIR expression
seems to be a good gene therapy candidate in HNSCC.
UCA1.  Urothelial cancer-associated 1 (UCA1) long non-
coding RNA is thought to participate in bladder cancer
invasion and progression. Expression level of UCA1  is sig-
nificantly enhanced in tongue squamous cell carcinoma
(TSCC) and it is correlated with metastasis to lymph nodes.
reports of practical oncology and radio
Table 1 – Targets of lncRNAs described as deregulated in
HNSCC.
lncRNA Targets
HOTAIR miR-124, miR-130a, miR-331-3p, -catenin, Bmi1,
CD11b, CD18, CD44, CD82, CD133, E-cadherin,
HoxA1, HoxA4, HoxA5, HER2, KRT8, p16, p21,
p53, PTEN, QKI, RBM38, SFN, WIF-1, MMP1,
MMP2, MMP3, MMP9, MMP13, N-cadherin, Slug,
Snail, Twist, VCAN, VEGF, Vimentin, Zeb1, Oct4
HOTTIP HoxA7, HoxA9, HoxA10, HoxA11, HoxA13
UCA1 p21, CDKN2B, EP300, TGF-2, WNT6, AKT, CREB,
p42, p44, ATM, Fas, PDGFB
LET CASP3, BCL2, PCNA, Bax, p21
MEG3 CASP3, CASP9, p53, LC3-II, COL1A1, MDM2,
-SMA, CASP8, Dll4, Hes1, Iqgap1, MMP9, Timp1,
Vegfa, Vegfr1, Wasl, BCL2, Bax, Cyto c, NF-kB
MALAT1 CCT4, CTHRC1, FHL1, ROD1, SLC26a2, TMEM20,
AKT, p38, PI3Kp85,  -catenin, CA2, E-cadherin,
HNF4G, MIA2, RASSF6, ROBO1, ABCA1,
ADAMTS12, AIM1, AKAP9, BMPER, CDCP1,
COL6A1, CPM, CSF1, CXCL5, DRD1, GPC6, HMMR,
LAYN, LPAR1, LPHN2, LY6K, MCAM, NNMT,
PRKCE, Slug, Snail, STC1, Vimentin, Zeb1, Zeb2,
ICAM, MMP9, PCNA, TNF-, VEGF, Fibronectin,
LTBP3, N-cadherin, p21
H19 let-7, miR-141, miR-200a, miR-200b, miR-200c,
miR-429, miR-675, N-cadherin, Snail, Twist,
Vimentin, Zeb1, Zeb2, Claudin1, E-cadherin,
KRT19, KRT8, p53, Bax, IGF2, COL2A1, Lnsr, Lpl,
Slug, CDH13, DICER, Hmga2, AKT, CDC25A,
GSK3
CDKN2B-AS1 ADIPOR1, C11ORF10, VAMP3, CARD8, Klf2, p21
GAS5 miR-21, CDK6, C-myc, ATG7, Beclin, Cyclin D1,
E2F1, LC3-II, ADAMTS4, MMP13, MMP2, MMP3,
MMP9, p21, p53, PDCD4, PTEN
linc-ROR miR-145, miR-181, miR-205, miR-99, E-cadherin,
Occludin, Fibronectin, N-cadherin, Vimentin,
-SMA, Zeb1, Zeb2, Nanog, Oct4, Sox2
XIST X-chromosome, Atrx, Fgd1, Huwe1
FOXCUT MMP2, MMP7, MMP9, VEGF, FoxC1
NEAT-1 HIV-1, ADARB2, EIF4G3, FP15737, OVC10-2,
SH3PXD2A, F11R (JAM1)


















expression. The role of MALAT1 in cancer progression was  alsodatabase (http://bioinformatics.ustc.edu.cn/lncreg/index.php).
oreover, higher expression of UCA1 was detected in lymph
ode metastasis than in primary tumors. In cell culture of
ongue squamous cell carcinoma, artificial over-expression of
CA1 promotes cells migration but has little impact on cell
roliferation. These observations suggest that UCA1 might
romote cancer cell metastasis and could be used as a prog-
ostic indicator of lymph node metastasis in TSCC.58 It was
lso found that UCA1 is expressed at higher level in OSCC.53
LET. In NPC patients, LET is significantly down-regulated
n cancer tissue compared to normal ones and it is corre-
ated with clinical stage, larger tumor size and invasion to
ymph nodes. NPC patients with low expression of LET have
oor recurrence-free survival and overall survival. In CNE2
ell line, enhanced LET expression inhibited cell prolifera-
ion and induced cell apoptosis by up-regulating the level of
leaved Caspase-3. Cells with over-expression of LET show
educed tumor growth in a nude mouse in vivo model. On
he other hand, repression of LET promotes cell proliferationtherapy 2 2 ( 2 0 1 7 ) 378–388 383
and inhibits apoptosis of NPC cells. It was found that LET is
repressed by specific methylation of histone H3K27me3 on the
LET promoter by enhancer of zeste homolog 2 (EZH2). More-
over, expression level of LET is inversely correlated with EZH2
in NPC tissues.59
MEG3.  The expression of maternally expressed gene 3
(MEG3) in TSCC tissues is significantly reduced compared to
nonmalignant tissue. The same phenomenon was observed in
tongue cell lines SCC-15 and CAL-27 in comparison to human
oral keratinocyte (HOK).60 Expression of MEG3 is correlated
with tumor size and its low level is associated with poor over-
all survival of TSCC patients. Reduced expression of MEG3
was also reported in hepatocellular carcinoma, gliomas60 and
OSCC.53 On the other hand, it was indicated that expression of
MEG3 correlated with miR-26a and higher expression of them
is associated with better overall survival of TSCC patients.
Moreover, expression of miR-26a and MEG3 is inversely cor-
related with methyltransferase DNMT3B. Over-expression of
miR-26a or MEG3 in tissue cells and cell lines causes inhi-
bition of cell proliferation, cell cycle arrest, and promotes
apoptosis.60
MALAT1. Metastasis associated lung adenocarcinoma tran-
script 1 (MALAT1) is encoded inside the transcript of
non-coding nuclear-enriched abundant transcript 2 (NEAT2)61
and regulates gene expression as well as posttranscription-
ally modification of primary transcripts.62 It was shown that
3′ end of MALAT 1 plays a crucial role in the regulation of
cell proliferation, migration and invasion.62 It is positively
correlated with clinical stage and serves as an oncogene in
esophageal squamous cell carcinoma, glioma, renal cell car-
cinoma, lung and pancreas cancer.61 Like in other cancers,
MALAT1 is also over-expressed in HNSCC such as laryngeal,62
tongue and oral squamous cell carcinomas63—especially
in the case of metastatic TSCC.64 In OSCC, MALAT1 is
associated with poor prognosis and patients with low
MALAT1 expression have significantly increased overall
survival.
In oral cell lines inhibition of MALAT1 resulted in reduced
cell invasion and migration, probably by regulation of MMP-
2/9. Its over-expression induces a strong invasion capability by
degradation of extracellular matrix in cancer cells.63 Addition-
ally, Fang et al. showed that MALAT1 modulates metastasis
process of TSCC partially by the regulation of SPRR (small
proline rich proteins) and genes associated with extracellu-
lar matrix and cytoskeleton regulation (LAYN, CCT4, CTHRC1
or FHL1). The knockdown of MALAT1 in SCC-25 and CAL-27
cell lines reduced cell migration ability and development of
distant metastasis.64
Moreover, MALAT1 is associated with the epithelial-to-
mesenchymal transition (EMT) process of OSCC in vitro.
Knockdown of MALAT1 in Tca8113 and Tscca cell lines induces
expression of E-cadherin and suppresses N-cadherin and
Vimentin.63 Also, reduction of -catenin and impact on NF-B
signaling pathways were reported as a result of MALAT1 inhi-
bition. It is well known that -catenin plays a key role in cell
invasion and angiogenesis by stimulation of MMPs and VEGFobserved in vivo—its inhibition suppressed tumor growth of
Tscca cell line injected to xenograft model.63 All these findings
indicate that MALAT1 is associated with cancer progression by
d rad384  reports of practical oncology an
the regulation of multiple signaling pathways connected with
cell proliferation, differentiation, migration, and invasion.
H19. The lncRNA H19 is a paternally-imprinted gene
located in close proximity to the maternally-imprinted,
insulin-like growth factor-2 (IGF-2) gene on chromosome 11.65
The biological function of H19 has recently begun to be elu-
cidated. It has been shown that the expression level of H19
is up-regulated in many  cancer types, including esophageal
cancer, breast cancer, colorectal cancer, gastric cancer, bladder
cancer, and laryngeal squamous cell carcinoma.66 In HNSCC,
loss of imprinting of IGF2 or H19 may constitute a novel mech-
anism of the deregulation of growth-promoting genes in the
development of these types of cancers.67,68
In LSCC tissue samples, H19 is up-regulated and its over-
expression is correlated with the tumor grade, differentiation,
neck nodal metastasis, clinical stage and poorer overall
survival.66 Knock-down of H19 inhibited LSCC cell migra-
tion, invasion, and proliferation. It was also proved that H19
and miR-148a-3p are negatively correlated and miR148a-3p
is an inhibitory target for H19. However, over-expression of
miR148a-3p did not affect the H19 expression level. H19 pos-
itively regulates the expression of DNA methyltransferase
enzyme DNMT1 via miR-148a-3p inhibition.66
In NPC, H19 is over-expressed and correlated with enhancer
of zeste homolog 2 (EZH2). Interestingly, higher levels of H19
were observed in poorly differentiated NPC cell line com-
pared to the normal nasopharyngeal epithelial cell line.65,69
Over-expression of H19 also promotes cell invasion and H19
knock-down significantly suppressed the invasive ability of
NPC cell lines. Furthermore, H19 regulates EZH2 expression
by interacting with miR-630 and inhibiting its activity.69
lincRNA NAG7 (LINC00312). It is a long intragenic non-
coding RNA situated in the region of common allelic loss and
it is associated with NPC. However, NAG7 transcript is also
translated into protein—estrogen receptor repressor-10 (ERR-
10) and probably functions as both coding and non-coding
RNA.70 LINC00312 is significantly down-regulated in NPC sam-
ples and its expression is positively correlated with lymph
node metastasis and negatively correlated with clinical stage
and tumor size.71 Studies showed that up-regulation of NAG7
inhibits proliferation (G1/S arrest) and increases cell adhesion,
motility, and invasion.72
Zhang et al. observed that clinical significance of LINC00312
expression level is connected with a lymph node status. In
the case of patients without lymph node metastasis, the high
expression of LINC00312 is associated with better DFS and OS.
On the other hand, in patients with positive lymph nodes, the
higher expression of LINC00312 is significantly connected with
poor DFS and OS. Moreover, LINC00312 is negatively correlated
with EBER-1 (non-coding RNA expressed in cells infected by
EBV virus) and authors speculate that EBER-1 may regulate
LINC00312 and have influence on cell behavior.72
Other lncRNAs. Unfortunately, the current knowledge about
lncRNAs in HNSCC is still poor and ambiguous. Although
there are comprehensive studies with regard to expres-
sion profiles of lncRNAs in HNSCC, they are not consistent.
Moreover, there is little information about functional roles
of lncRNAs in HNSCC. The available information about
lncRNAs—which were indicated but very cursorily described
in some studies—is presented in Table 2.iotherapy 2 2 ( 2 0 1 7 ) 378–388
4.  lncRNA  in  chemo-  and  radioresponse  of
HNSCC
It was presented that expression of lncRNA is changed after
exposition to chemotherapeutic drugs and this phenomenon
could maintain drug resistance of cancer cell lines.38,62,82 Chen
et al. showed that CDKN2B-AS1 (ANRIL), HOTAIR and MALAT1
were significantly reduced in Hep-2 and AMC-HN8 cells with
the increasing concentration of cisplatin and paclitaxel. More-
over, the changes in the lncRNA expression continued for a
long time and the most reduction was visible when cells were
exposed to drug for 24 h. Unfortunately, authors did not con-
nect changes in CDKN2B-AS1 (ANRIL), HOTAIR, and MALAT1
expression after drug exposition with some targets playing
important roles in chemoresponse.62 Comparison of lncRNA
changes in paclitaxel-resistant CNE-2 and parental CNE-2
cell lines (nasopharyngeal) using NGS technology revealed
2670 known and 4820 novel lncRNAs. The most changed
lncRNAs—n375709, n377806, n369241, n335785, Unigene6646,
Unigene6644 and Unigene1654—were confirmed by qRT-PCR.
Knock-down of n375709 in NPC 5-8F and 6-10B cell lines
increased sensitivity to paclitaxel.38 One of the well-described
lncRNA regulating chemoresistant in NPC is lncRNA-ROR.
Li et al. showed that lncRNA-ROR is up-regulated in NPC
tissue and cell lines and regulates cell proliferation, cell
cycle, apoptosis, migration, and invasion. Moreover, knock-
down of ROR induces MET (up-regulation of E-cadherin and
down-regulation of Vimentin, N-cadherin, Zeb1 and Zeb2).
Application of cis-Dichlorodiamineplatinum (II) (DDP) to NPC
cell lines induced up-regulation of ROR. Knock-down of
lncRNA-ROR after incubation with DDP caused chemosen-
sitivity of the cells through regulation of p53 pathway.82
Only one study indicates lncRNAs as biomarkers to predict
response to chemoradiotherapy. It shows that plasma circu-
lating GAS5 is useful as a predicting biomarker. However, this
study analyzed only a small and non-homogeneous group of
patients, which might influence results.78
Up to date, one study describes the role of lncRNA in
radioresistant NPC cell lines. Radioresistant NPC cell line was
compared to parental one using NGS technology. In this study
310 up-regulated and 471 down-regulated known lncRNAs
and 406 up-regulated and 1648 down-regulated novel lncR-
NAs were dysregulated in radioresistant CNE-2-Rs cell line.
The up-regulated (n333177, n689, n375997, Unigene8485 and
Unigene8588) as well as down-regulated (n376834, n381831,
n375997, n341810 and Unigene3434 lncRNA) were confirmed
by qRT-PCR. Three pairs of lncRNA-mRNA were indicated:
n3739320-SLITRK5, n409627-PRSS12 and n386034-RIMKLB.
However, after 4 Gy irradiation of two different radioresistant
NPC cell lines, only slight changes of these lncRNAs-mRNAs
pairs were observed in CNE-2-Rs cell line. In the case of the sec-
ond radioresistant 6-10B-RS cell line, strong down-regulation
of n373932 lncRNA and up-regulation of STITRK5 mRNA  were
observed and both of them are negatively correlated in NPC
patients.29 It should be noted that some reports indicated that
83CNE-2 cell line could be contaminated by HeLa cell line,
so the obtained results should be verified. The exact role of
lncRNA in different subtypes of HNSCC regarding to radiore-
sponse has remained unevaluated.
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Table 2 – Other lncRNAs described as dysregulated in HNSCC.
lncRNA Description Ref.
NEAT-1 - The most abundantly expressed lncRNA in normal oral mucosa
- One of the least stable lncRNA
- Overexpressed in OSCC tissues but not found in patients’ saliva
- Overexpressed in LSCC, especially in advanced and neck nodal metastasis
cancers
- Regulator of proliferation, invasion, influence on cell cycle, inducer of
apoptosis and tumor growth in xenografts
- Regulator of CDK6 expression through up-regulation of miR-107
33,53,73,74
CDKN2B-AS1 - Up-regulated in LSCC
- Inversely regulated by cisplatin and paclitaxel
62
HOTTIP - Up-regulated in TSCC; associated with clinical stage, tumor size and distant
metastasis
- Higher expression significantly associated with patients’ OS; an
independent poor prognostic factor
75
RRP1B - Down-regulated in LSCC 62
SRA1 - Down-regulated in LSCC
- Unique modulator of steroid receptor transcriptional activity
62
AC026166.2-001 (MTCO1P5) - Down-regulated in LSCC tissues and metastatic cervical lymph nodes




-  Down-regulated in LSCC and significantly associated with cervical lymph
node metastasis
- Low expression correlated with poor prognosis
- Potential role in tumorigenesis and migration of LSCC
76
GAS5
-  Down-regulated in HNSCC and correlated with poor prognosis
- Inducer of apoptosis process
- Circulating GAS5 level as presumable predictor of patients’ response to
radical chemoradiotherapy with high sensitivity and specificity
33 77 78
lnc-JPHl-7 - Significantly associated with survival of both HPV+ and HPV- patients,
advanced tumor stage, KMT2D mutation, TP53 mutation and 3p deletion





-  Down-regulated in patients samples and cell lines
- Influence on EMT process and cancer stem cells—up-regulated
lnc-KTCTD6-3 increases E-cadherin and reduces OCT4, NANOG and
Vimentin expression; up-regulated lnc-LCE5A-1 reduces NANOG, BMI, TWIST
and Vimentin expression
- High expression reduces cell migration and proliferation
33
XIST - Up-regulated in NPC samples and NPC cancer cell lines
- Connected with poorer OS, an independent risk factor for prognosis
- Regulator of cell growth
- Influence on up-regulation of oncogene E2F3 through ‘spongeing’
miR-34a-5p
79
FOXCUT - Over-expressed in OSCC samples
- Positively correlated expression of FOXCUT and FOXC1
- Regulator of cell proliferation, colony formation and invasion; influence on
expression of MMP2, MMP7, MMP9 and VEGF-A
80
NKILA - Down-regulated in TSCC; correlated with clinical parameters,














- Over-expression of NKILA
ability through regulation 
.  Conclusions  and  future  perspectives
ead and neck cancers are the most fatal. In clinical practice,
atient’s molecular profile of a tumor is not commonly used
o personalized treatment. This molecular puzzle is now com-
leted by a new element—long non-coding RNAs. However,
nly seven lncRNA profiling studies are reported and the
hanges in the expression during carcinogenesis process is
till not clear in HNSCC. Moreover, these studies show many
nconsistencies and, in our view, more  independent screen-
ngs are needed. The open question is still the functional roleces invasion and migration cancer cell
-kB pathway and influence on EMT process
of deregulated lncRNA in HNSCC. Biological role and targets of
several lncRNAs were barely verified in vitro or in vivo. These
described lncRNAs play important roles in cell proliferation,
cell cycle, apoptosis, migration and invasion, angiogenesis,
EMT  process as well as probably in maintenance of CICs popu-
lations. However, this statement needs to be verified by more
experiments, various models and clearer evidence, which
show changes in specific cellular processes such as the reg-
ulation of CICs populations. CICs seem to arise in early steps
of tumorigenesis and they are responsible for cancer devel-
opment. However, CIC-related lncRNAs are still not clearly
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be described. It is well documented that aggressiveness and
poor response to radio- and chemotherapy of HNSCC depends
on distinct populations of CICs. The discovery of CIC-related
lncRNAs may help to design the gene therapy strategies. The
next problem that should be clarified is the role of lncRNA
in radio- and chemical response. Only two screening experi-
ments were performed in NPC cell lines to discover function of
specific lncRNAs in radio- and chemoresistance, so the exact
role needs to be verified more  thoroughly. The use of rela-
tion of lncRNAs and cancerogenesis may dramatically change
the HNSCC therapy and improve patients’ outcome. Firstly,
in diagnostics assessment of lncRNA, expression profile could
describe the molecular portrait of a tumor and predict treat-
ment strategies and their effectiveness. Secondly, the use of
lncRNAs as gene therapy drugs is supposed to deplete CICs
or reverse their phenotype consequently sensitizing cancer
cells on the effect of the radio- and chemotherapy. However,
this is still an intention. We should collect more  information
about lncRNAs and not forget the different elements of cancer
biology.
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